⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DNLI News
Denali Therapeutics Inc. Common Stock
Form 8-K
sec.gov
DNLI
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
globenewswire.com
DNLI
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
globenewswire.com
WVE
ALNY
DNLI
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
globenewswire.com
DNLI
ISPE Announces 2026 Facility of the Year Awards (FOYA) Submission Finalists at the 2026 ISPE Facilities of the Future Conference
prnewswire.com
AZN
DNLI
LLY
JNJ
MRK
MRNA
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
globenewswire.com
DNLI
Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™
globenewswire.com
DNLI
Press Registration Is Now Open for the 2026 ACMG Annual Clinical Genetics Meeting
prnewswire.com
BMRN
DNLI
ONOF
SNY
Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome
globenewswire.com
DNLI
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
globenewswire.com
DNLI